Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 2/20 | 0.30 |
| ▸ | XIAP | P98170 | 1/20 | 0.30 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20049289 | 0.80 | RAB9A (0.43) | TLR8TLR7MAPT | |
| SCHEMBL20043218 | 0.80 | CASR (0.33) | MAPTCASR | |
| SCHEMBL22672406 | 0.74 | TLR8 (0.47) | TLR8TLR7 | |
| SCHEMBL20047562 | 0.74 | ATM (0.33) | TLR8TLR7MAPTCASR | |
| SCHEMBL12210439 | 0.73 | XIAP (0.51) | TLR8TLR7MAPTLOXL2XIAP | |
| SCHEMBL16880370 | 0.71 | IDO1 (0.43) | TLR8TLR7MAPT | |
| SCHEMBL20047532 | 0.70 | LIPG (0.39) | TLR8TLR7MAPTLOXL2CASR | |
| SCHEMBL20047486 | 0.69 | HSD17B10 (0.38) | TLR8TLR7CASR | |
| SCHEMBL9193166 | 0.69 | ALDH1A1 (0.36) | KIF11 | |
| SCHEMBL22672404 | 0.69 | SMN1; SMN2 (0.33) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | TLR8 901/4885TLR7 491/4885MAPT 4191/4885 |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | GPBAR1, SLC10A1, NR1H4 | TLR8 901/4885TLR7 491/4885MAPT 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.